Every country decides for itself which medicines may be sold inside its borders. The bodies that make those decisions are the pharma regulatory authorities, and if you export medicines, they set the rules you work under.
There is no single global licence. A product approved in one market has no standing in another, even when the dossier, the factory, and the batch are identical.
Some authorities run full scientific reviews with their own inspectors. Others lean on decisions made elsewhere. This guide covers what a national authority does, how WHO classifies regulatory systems, and then works through the major agencies region by region.
What are pharma regulatory authorities? Pharma regulatory authorities are government bodies that control which medicines can be manufactured, imported, and sold in a country. They grant marketing authorisations, license manufacturers and importers, inspect facilities against GMP, monitor safety after launch, and order recalls when a product fails its approved standard.
Table of Contents
- What a Regulatory Authority Does
- WHO Maturity Levels and WHO-Listed Authorities
- What Stringent Regulatory Authority Means
- Reliance, Recognition, and Abridged Review
- The Americas
- Europe
- Asia-Pacific
- Middle East and Africa
- Eurasia
- Harmonisation Bodies and Pharmacopoeias
- Comparison Table of Major Authorities
- Expert Tips
- Common Mistakes
- Frequently Asked Questions
What a Regulatory Authority Does
The job is wider than approving products. Most exporters meet several of these functions over one registration.
Marketing authorisation. The licence allowing a specific product, made at a named site to a named formula, onto the market. Generic files lean on a reference product instead of fresh clinical trials.
GMP inspection. Some authorities inspect foreign sites themselves, some accept a partner agency’s report, some want both. A failed inspection can stop every product from that plant.
Licensing the local chain. Importers, wholesalers, and distributors need their own licences, and the authorisation is usually held by a locally registered entity.
Pharmacovigilance. After launch the authority collects adverse event reports and can restrict or withdraw the licence. Many markets require a named local safety contact.
Surveillance and recalls. Regulators sample products from pharmacies and ports, test them, and publish results. Failed batches get a recall classification with a deadline attached.
Clinical trial oversight. Trials need authority approval alongside ethics clearance, which generic exporters meet whenever a bioequivalence study supports the dossier.
WHO Maturity Levels and WHO-Listed Authorities
The World Health Organization assesses regulatory systems with its Global Benchmarking Tool (GBT), scoring registration, inspection, vigilance, laboratory testing, and licensing. The result is a maturity level from 1 to 4:
- ML1 — some elements of a regulatory system exist
- ML2 — an evolving system performing some core functions
- ML3 — a stable, well-functioning, integrated system
- ML4 — advanced, with continuous improvement
Reaching ML3 is a real milestone, and a growing number of authorities across Africa, Asia, and Latin America hold that designation.
A WHO-Listed Authority (WLA) is a regulator WHO has evaluated against the GBT and formally listed as meeting the required standard. UN agencies, global health funds, and national buyers use WLA status when deciding whose approvals to rely on.
What Stringent Regulatory Authority Means
Stringent Regulatory Authority (SRA) came out of WHO prequalification and donor procurement. It described regulators that were ICH members, observers, or associates under the arrangements in place as of October 2015 — in practice the US, the European system, Japan, Canada, Switzerland, and Australia.
The label froze a snapshot and excluded capable regulators that joined later, which is why WHO built the WLA framework as its successor. You will still see “SRA-approved” in tenders; check that tender’s own definition rather than assuming a fixed list.
Reliance, Recognition, and Abridged Review
Few authorities review every dossier from scratch, so most use pathways that draw on work done elsewhere.
Reliance means the authority considers another regulator’s assessment but still decides for itself. It may ask for the assessment report, approved labelling, and proof of marketing in the reference country.
Recognition goes further, accepting the reference decision largely as it stands subject to local requirements. Mutual recognition of GMP inspections works this way. Abridged or verification review is a shortened assessment for products already approved by a listed set of reference agencies.
For exporters the lesson is simple. An approval or Certificate of Pharmaceutical Product from a well-regarded authority often opens a faster route in a dozen other markets.
The Americas
US FDA (Food and Drug Administration) — Medicines sit with the Center for Drug Evaluation and Research. Generics go through the ANDA route, APIs through a Drug Master File, and site registration is mandatory. Its public databases let buyers verify most of your claims without asking you.
Health Canada — The Health Products and Food Branch reviews submissions and the Drug Product Database lists approvals. Canada issues its own establishment licences and accepts some foreign GMP evidence. Bilingual labelling is a genuine cost.
ANVISA (Brazil) — Agência Nacional de Vigilância Sanitária. An ICH and PIC/S member that inspects foreign sites and runs a separate route for the active substance dossier. Local representation and Portuguese translation are not optional.
COFEPRIS (Mexico) — Comisión Federal para la Protección contra Riesgos Sanitarios. Uses reliance arrangements with reference agencies and is a PAHO-recognised regional reference authority. A Mexican licence holder is required.
ANMAT (Argentina) — Administración Nacional de Medicamentos, Alimentos y Tecnología Médica. A PIC/S member that treats source countries differently by regulatory standing, so where your product is already approved matters.
INVIMA (Colombia) — Instituto Nacional de Vigilancia de Medicamentos y Alimentos. Another PAHO regional reference authority. It issues sanitary registrations and runs its own GMP certification of foreign sites.
Europe
Europe is the region most often misread, because assessment and approval sit in different hands.
EMA (European Medicines Agency) coordinates scientific assessment for the centralised procedure, drawing on national experts. It does not grant the licence.
The European Commission issues the EU-wide marketing authorisation once the EMA committee gives a positive opinion. Many generics never go centralised — national, mutual recognition, and decentralised procedures run through the national agencies instead.
EDQM — the European Directorate for the Quality of Medicines & HealthCare publishes the European Pharmacopoeia and issues the Certificate of Suitability (CEP). A CEP is accepted well beyond Europe.
National competent authorities include BfArM in Germany for most chemical medicines, with the Paul-Ehrlich-Institut covering vaccines and biologicals; ANSM in France; AIFA in Italy; and AEMPS in Spain. Choosing which one leads a decentralised application is a strategic decision.
MHRA (United Kingdom) — Medicines and Healthcare products Regulatory Agency. It now runs independent national procedures plus an International Recognition Procedure that takes account of approvals from trusted regulators. Northern Ireland arrangements have changed more than once, so confirm the current position.
Swissmedic (Switzerland) reviews independently of the EU and also operates a dedicated procedure for medicines intended for markets outside Switzerland.
Asia-Pacific
CDSCO (India) — Central Drugs Standard Control Organization, under the Directorate General of Health Services. It handles import registration, new drug approval, and trial permissions, while State Licensing Authorities issue manufacturing and sale licences. Both levels matter.
NMPA (China) — National Medical Products Administration, reorganised from the former CFDA in 2018. Its Center for Drug Evaluation performs technical review. China is an ICH member; Chinese-language dossiers and a local agent are required.
PMDA (Japan) — Pharmaceuticals and Medical Devices Agency performs review and GMP inspection, while the Ministry of Health, Labour and Welfare grants approval. Japanese pharmacopoeial expectations apply.
MFDS (South Korea) — Ministry of Food and Drug Safety. A PIC/S and ICH member with its own GMP evaluation for imported products and detailed scrutiny of manufacturing documentation.
TGA (Australia) — Therapeutic Goods Administration. The Australian Register of Therapeutic Goods publicly shows what is approved and who holds it. Overseas manufacturers need GMP clearance, often granted on a foreign inspection report.
Medsafe (New Zealand) — A smaller, pragmatic system inside the Ministry of Health that draws on assessments from comparable regulators where appropriate.
HSA (Singapore) — Health Sciences Authority. Runs tiered evaluation routes depending on prior approval by designated reference agencies, and is a PIC/S member.
NPRA (Malaysia) — National Pharmaceutical Regulatory Agency, under the Ministry of Health. Registers products and grants GMP recognition to foreign sites.
BPOM (Indonesia) — Badan Pengawas Obat dan Makanan. Registers medicines and inspects overseas manufacturers. Halal requirements sit alongside registration as a separate workstream.
FDA Philippines — Issues Certificates of Product Registration and licenses local importers. Both product and establishment must be licensed before goods clear customs.
DAV (Vietnam) — Drug Administration of Vietnam, under the Ministry of Health, issues registration numbers and has moved towards reliance on stringent reference approvals for some applications.
Thai FDA (Thailand) — Registers medicines and licenses importers, with documentation shaped by ASEAN harmonisation work.
Across ASEAN the ACTD dossier structure is still used in several countries, though many now accept ICH CTD as well. Confirm the expected structure before compiling.
Middle East and Africa
SFDA (Saudi Arabia) — Saudi Food and Drug Authority registers both the product and the manufacturing site and conducts its own overseas inspections. Registration generally precedes any commercial import, including for tenders.
UAE — MOHAP and the Emirates Drug Establishment — Registration has historically sat with the Ministry of Health and Prevention. The Emirates Drug Establishment was created as a federal medicines body and its remit has been phasing in. Because functions have been transferring, confirm the current allocation directly before submitting.
SAHPRA (South Africa) — South African Health Products Regulatory Authority replaced the Medicines Control Council in 2018 and applies reliance-based review for products cleared by recognised regulators.
NAFDAC (Nigeria) — National Agency for Food and Drug Administration and Control. Registers medicines, inspects foreign sites, and requires a local representative.
EDA (Egypt) — The Egyptian Drug Authority was established as an independent body, consolidating functions previously spread across Ministry of Health bodies. Pricing approval is a separate step from registration.
PPB (Kenya) — The Pharmacy and Poisons Board registers medicines, licenses premises, and inspects foreign manufacturers, sometimes through East African joint assessment work.
African Medicines Agency — Established through an African Union treaty that has entered into force, with the aim of coordinating regulation across the continent. Operationalisation is ongoing and does not yet replace national registration, so keep planning country by country.
Eurasia
EAEU framework — The Eurasian Economic Union operates a common medicines framework covering Armenia, Belarus, Kazakhstan, Kyrgyzstan, and Russia, with applications made through a reference member state. The shift from national registrations to the union format has run with transition arrangements and revised deadlines, so verify the current position per country.
Russia — The Ministry of Health grants registration. Roszdravnadzor is the supervisory service handling inspection, surveillance, quality control, and enforcement. Russian GMP certification of foreign sites is a separate project with its own lead time.
Harmonisation Bodies and Pharmacopoeias
These bodies do not approve products. They write rules that authorities then adopt.
ICH — the International Council for Harmonisation produces the technical guidelines behind modern dossiers: the CTD structure, stability under the Q1 series, impurities under Q3, quality risk management under Q9.
PIC/S — the Pharmaceutical Inspection Co-operation Scheme aligns GMP inspection standards, making it easier for one authority to accept another’s findings.
WHO Prequalification — WHO assesses selected medicines, vaccines, and diagnostics so UN agencies and donors can procure with confidence. It also carries weight with national regulators.
ISO — publishes standards used across pharmaceutical operations, including quality management, cleanroom classification, and device quality systems.
Pharmacopoeias set quality standards rather than granting approvals: USP–NF (United States), Ph. Eur. (Europe), BP (United Kingdom), IP (India), JP (Japan), and ChP (China). Limits and methods for the same substance can differ between them, so your certificate of analysis must state which one you tested against — and it must match what the destination accepts.
Comparison Table of Major Authorities
| Authority | Country / region | Dossier format | Public database | Notable for exporters |
|---|---|---|---|---|
| US FDA | United States | eCTD | Drugs@FDA, Orange Book | DMF and ANDA system; open inspection records |
| European Commission / EMA | European Union | eCTD | EMA medicines database | Commission grants licence, EMA assesses |
| MHRA | United Kingdom | eCTD | MHRA products site | National routes plus international recognition |
| Swissmedic | Switzerland | eCTD | Authorised medicines list | Independent review; global health route |
| Health Canada | Canada | eCTD | Drug Product Database | Bilingual labelling; establishment licensing |
| ANVISA | Brazil | CTD-based | Product consultation portal | ICH and PIC/S member; separate API route |
| COFEPRIS | Mexico | CTD-based | COFEPRIS registry | Reliance routes; local holder required |
| CDSCO | India | CTD-based | CDSCO listings | Central plus state licensing; source of CoPP |
| NMPA | China | CTD-aligned, Chinese | NMPA database | ICH member; local agent essential |
| PMDA / MHLW | Japan | eCTD | PMDA approval information | PMDA reviews, ministry approves |
| MFDS | South Korea | CTD-based | MFDS product information | PIC/S and ICH member; detailed GMP review |
| TGA | Australia | eCTD | ARTG | Register names the sponsor; GMP clearance |
| HSA | Singapore | ACTD or ICH CTD | HSA register | Tiered routes based on prior approvals |
| SFDA | Saudi Arabia | CTD-based | SFDA drug list | Registers product and site; own inspections |
| SAHPRA | South Africa | CTD-based | Registered products list | Reliance review from recognised regulators |
| NAFDAC | Nigeria | CTD-based | NAFDAC green book | Foreign site inspection; local representative |
Requirements change regularly. Confirm against the authority’s current guidance before compiling any submission.
Expert Tips
- Map the authority before you map the customer. Two buyers in the same region can face very different registration burdens. Check the route first, then price the opportunity.
- Keep a live matrix of site approvals. Record which authorities have inspected or accepted each site, with dates and certificate references. Buyers ask constantly, and hunting for it later costs weeks.
- Get the Certificate of Pharmaceutical Product wording exact. Files are rejected because the product name, strength, or manufacturing address does not match the dossier character for character.
- Track pharmacopoeial revisions, not just monographs. A revised monograph can change a specification you already registered. Build the check into your annual product review.
- Choose your first approval strategically. If reliance markets are on your list, an early approval from a widely recognised authority shortens several later applications.
- Budget for local presence, not just paperwork. Licence holders, responsible pharmacists, and safety contacts are recurring costs that exporters routinely leave out of a quotation.
- Read the variation rules before changing anything. Switching a supplier, site, or packaging component often needs prior approval. Changing first and filing later is how licences get suspended.
Common Mistakes
- Assuming EMA grants the licence. The European Commission does, on EMA’s opinion — misdirected correspondence delays the file.
- Treating “SRA-approved” as a fixed list. Tenders define it differently and the term is being replaced. Guessing can disqualify a bid.
- Using one dossier format everywhere. Sending ICH CTD where ACTD is expected fails at validation before technical review starts.
- Ignoring state or provincial licensing. In India and elsewhere, national approval is not the whole picture, and a missing local licence stops the shipment.
- Letting a GMP certificate expire mid-review. Validity is usually required at assessment, and an expired certificate can send the application back to the queue.
- Trusting an agent’s summary over the authority’s guidance. Outdated agent advice is a common cause of avoidable rejection.
- Underestimating translation and labelling. Language rules, local warnings, and pack size limits often force artwork rework, delaying first shipment by months.
Frequently Asked Questions
What are pharma regulatory authorities?
Pharma regulatory authorities are government agencies that control medicines within a country or region. They decide which products may be sold, license manufacturers and importers, inspect factories against GMP standards, and monitor safety after launch. They also sample the market, order recalls, and approve clinical trials. Examples include the US FDA, the European Medicines Agency working alongside the European Commission, CDSCO in India, and NMPA in China. Each works under its own national law, so requirements differ market by market.
Is there a single global drug approval?
No. There is no worldwide marketing authorisation. Every country or bloc grants approval under its own legislation. The closest thing to a multi-country licence is a regional system such as the EU centralised procedure or the Eurasian Economic Union framework, and those cover only member states. What does cross borders is trust in another regulator’s work: many authorities operate reliance or recognition pathways that shorten review when a product is already approved by an agency they respect.
What is a WHO-Listed Authority?
A WHO-Listed Authority is a regulator that the World Health Organization has evaluated using its Global Benchmarking Tool and formally listed as meeting a defined performance standard. The framework gives procurement agencies, donors, and national regulators an evidence-based way to decide whose decisions they can rely on. It was designed to replace informal labels such as Stringent Regulatory Authority with something transparent and periodically reassessed. For exporters, approval by a listed authority can support faster review in reliance markets.
What does Stringent Regulatory Authority mean?
Stringent Regulatory Authority, or SRA, describes regulators that were ICH members, observers, or associates under arrangements in place as of October 2015. It became shorthand in donor procurement for a highly regarded regulator, covering agencies such as the US FDA, EU authorities, Japan, Canada, Switzerland, and Australia. The term is being phased out in favour of the WHO-Listed Authority framework but still appears in tenders. When you see it, check the definition used in that specific tender rather than assuming a standard list.
Which authority approves medicines in Europe?
For centrally authorised medicines, the European Medicines Agency runs the scientific assessment and the European Commission grants the marketing authorisation valid across the EU. Many generics instead use national, mutual recognition, or decentralised procedures handled by national competent authorities such as BfArM in Germany, ANSM in France, AIFA in Italy, and AEMPS in Spain. The United Kingdom now operates separately through the MHRA, and Switzerland has always sat outside the EU system under Swissmedic.
What is the difference between a pharmacopoeia and a regulatory authority?
A pharmacopoeia is a book of legally recognised quality standards. It defines how a substance is identified, which impurities are permitted, and what test methods apply. Examples include USP–NF, the European Pharmacopoeia, the British Pharmacopoeia, the Indian Pharmacopoeia, the Japanese Pharmacopoeia, and the Chinese Pharmacopoeia. A regulatory authority is a government body that enforces those standards through approvals, inspections, and market testing. Pharmacopoeias set the specification; authorities decide whether you may sell against it.
Which authority controls pharmaceutical exports from India?
The Central Drugs Standard Control Organization is the national authority, working under the Directorate General of Health Services. It handles import registration, new drug approvals, and clinical trial permissions, and supports export documentation such as the Certificate of Pharmaceutical Product. Manufacturing and sale licences are issued separately by State Licensing Authorities. Exporters therefore deal with both levels, and depending on the product and destination other bodies such as export promotion councils may also be involved in certification.
Do I need a local company to register a medicine abroad?
In most countries, yes. The marketing authorisation is usually held by a locally registered entity, and many markets also require a licensed importer, a responsible pharmacist, and a named pharmacovigilance contact. Some authorities allow a foreign manufacturer to hold the registration through an appointed local agent instead. The arrangement decides who controls the licence if the commercial relationship ends, which is why the agency agreement deserves as much attention as the dossier.
Final Thoughts
Regulatory authorities look intimidating from outside, but the pattern behind them is stable. A small group of agencies sets the technical direction, harmonisation bodies spread it, and most other regulators adapt it to local law and capacity.
Once you know where a market sits on that map, you can predict what it will ask for. That turns registration planning from guesswork into a schedule.
Work With a Partner Who Knows the Paperwork
Choosing a market is a regulatory decision as much as a commercial one. If you are planning a registration or need documentation prepared to a specific authority’s expectations, discuss your sourcing requirements with our team and we will tell you plainly what the route involves.